Acarix ABACIXF 47 Quick Ratio is 4.76 as of Mar. 2026, which is 31% below its 10-year median of 6.88. GuruFocus rates ACIXF with a GF Score™ of 47/100 and a GF Value™ of $0.02 (Significantly Overvalued). The stock has 1 warning sign investors should review. Among 854 Medical Devices & Instruments companies, Acarix AB ranks better than 81.97% on this metric.
The quick ratio measures a company's ability to meet its short-term obligations with its most liquid assets. It is calculated as a company's Total Current Assets excludes Total Inventories divides by its Total Current Liabilities. Acarix AB's quick ratio for the quarter that ended in Mar. 2026 was 4.76.
Acarix AB has a quick ratio of 4.76. It generally indicates good short-term financial strength.
The historical rank and industry rank for Acarix AB's Quick Ratio or its related term are showing as below:
ACIXF'
s Quick Ratio Range Over the Past 10 Years
Min: 0.35 Med: 6.88 Max: 42.15
Current: 4.77
During the past 12 years, Acarix AB's highest Quick Ratio was 42.15. The lowest was 0.35. And the median was 6.88.
ACIXF's Quick Ratio is ranked better than 81.97% of 854
companies
in the Medical Devices & Instruments industry
Industry Median: 1.865
vs ACIXF: 4.77
Acarix AB (OTCPK:ACIXF) Quick Ratio Explanation
The quick ratio is more conservative than the Current Ratio because it excludes inventories from current assets. The ratio derives its name presumably from the fact that assets such as cash and marketable securities are quick sources of cash. Inventories generally take time to be converted into cash, and if they have to be sold quickly, the company may have to accept a lower price than book value of these inventories. As a result, they are justifiably excluded from assets that are ready sources of immediate cash.
In general, low or decreasing quick ratios generally suggest that a company is over-leveraged, struggling to maintain or grow sales, paying bills too quickly or collecting receivables too slowly. On the other hand, a high or increasing quick ratio generally indicates that a company is experiencing solid top-line growth, quickly converting receivables into cash, and easily able to cover its financial obligations. Such companies often have faster inventory turnover and cash conversion cycles.
The higher the quick ratio, the better the company's liquidity position.
Acarix AB Quick Ratio Related Terms
Acarix AB Quick Ratio Historical Data
* Premium members only.
The historical data trend for Acarix AB's Quick Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Devices subindustry, Acarix AB's Quick Ratio, along with its competitors' market caps and Quick Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Acarix AB Quick Ratio vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Acarix AB's Quick Ratio distribution charts can be found below:
* The bar in red indicates where Acarix AB's Quick Ratio falls into.
The quick ratio measures a company's ability to meet its short-term obligations with its most liquid assets. For this reason, the ratio excludes inventories from current assets.
Acarix AB's Quick Ratio for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Acarix AB (ACIXF) has a Quick Ratio of 4.76 as of Mar. 2026. Quick ratio is the ratio of current assets less inventory to current liabilities. View historical data on Acarix AB and its competitors. This is 31% below median its historical median of 6.88. Over the past decade, Acarix AB's Quick Ratio has ranged from 0.35 to 42.15. According to the industry distribution chart, Acarix AB ranks #154 out of 854 companies in the Medical Devices & Instruments industry, placing it in the top 18%.
Is Acarix AB's Quick Ratio too high?
Acarix AB's current Quick Ratio of 4.76 is 31% below median its 10-year median of 6.88. Over the past 10 years, this metric has ranged from a low of 0.35 to a high of 42.15. The Medical Devices & Instruments industry median Quick Ratio is 1.87. Acarix AB's value of 4.76 is 155.2% above this industry median. Based on the distribution chart, Acarix AB ranks #154 out of 854 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, Acarix AB has a GF Score™ of 47/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Acarix AB's Quick Ratio compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Acarix AB ranks #154 out of 854 companies for Quick Ratio. This places Acarix AB in the top 18% of its industry — outperforming the majority of peers. The industry median Quick Ratio is 1.87. Acarix AB's value of 4.76 is 155.2% above this benchmark. Historically, Acarix AB's own Quick Ratio has ranged from 0.35 to 42.15 over the past decade. While the company's 10-year median is 6.88 vs. the industry median of 1.87, Acarix AB has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Quick Ratio for a Medical Devices & Instruments company?
The median Quick Ratio among Medical Devices & Instruments companies is 1.87, based on 854 companies in the industry. Companies in the top quartile (top 25%) have a Quick Ratio significantly above this median, while those in the bottom quartile fall well below. However, Quick Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Acarix AB's current Quick Ratio of 4.76 is 155.2% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Quick Ratio mean?
A high Quick Ratio can signal that a stock is expensive relative to its fundamentals. Quick ratio is the ratio of current assets less inventory to current liabilities. View historical data on Acarix AB and its competitors. For the Medical Devices & Instruments industry, the median Quick Ratio is 1.87 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Acarix AB's current Quick Ratio is 4.76, which is 31% below median its own 10-year median of 6.88. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Acarix AB stock overvalued right now?
Based on GuruFocus' analysis, Acarix AB (ACIXF) is currently considered Significantly Overvalued. The stock's GF Value™ is $0.02, compared to a current price of $0.03 — trading 45% above its estimated fair value. The current Quick Ratio is 4.76, which is 31% below median its 10-year median of 6.88 and 155.2% above the Medical Devices & Instruments industry median of 1.87. Acarix AB's overall GF Score™ is 47/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Quick Ratio calculated?
Quick Ratio is calculated from a company's financial statements. For Acarix AB (ACIXF), the current Quick Ratio is 4.76 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Acarix AB (ACIXF) Overvalued in 2026?
Based on GuruFocus' analysis, Acarix AB stock appears to be overvalued.
The current stock price of $0.03 is trading 45% above its estimated GF Value™ of $0.02.
GuruFocus considers Acarix AB to be Significantly Overvalued.
Key valuation signals for ACIXF:
Quick Ratio: 4.76 (31% below median its 10-year median of 6.88)
GF Value™: $0.02 vs. price of $0.03 (45% above fair value)
Industry Position: 155.2% above the Medical Devices & Instruments median (#154 of 854)
No single metric tells the full story. See the ACIXF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Acarix AB is a Swedish medical technology company that develops solutions for rapid AI-based exclusion of coronary artery disease (CAD). Its CE-marked CADScor System, which has also received DeNovo approval from the FDA, is intended for patients experiencing chest pain with suspected coronary artery disease and is designed to help reduce millions of cases of unnecessary, invasive, and costly diagnostics. Acarix recommends the CADScor System as a first-line diagnostic tool that uses sensitive acoustics and computational processing to analyze coronary blood flow to rule out coronary artery disease (CAD), with a majority certainty at the point of care. Geographically, the company generates maximum revenue from the United States, and the rest from Germany, Sweden, Iraq, and other regions.
47GF Score
Get the complete analysis for ACIXF
Quick Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ACIXF has been successfully added to your 
